Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Capecitabine (Primary) ; Neratinib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 21 Mar 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.